ArticlePediatric gastroenterology, hepatology & nutrition2025
Supplementation of 2'-Fucosyllactose in Formula-Fed Infants Has Potential Benefits to Reduce the Risks of Infantile Colic and Atopic Dermatitis in Infancy.
Article in Pediatric gastroenterology, hepatology & nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Human milk oligosaccharides (HMOs) are non-digestible carbohydrates found in breast milk, with 2'-fucosyllactose (2'-FL) being a prominent type. This study examined the effects of HMOs on the incidence of infantile colic (IC) and atopic dermatitis (AD) in full-term infants who were breastfed (BM), formula-fed (FF), or fed formula supplemented with 2'-fucosyllactose (FF_2'-FL) for 1 year. Methods: This open-label, prospective clinical trial enrolled 338 full-term infants from 2020 to 2024. IC was diagnosed using the ROME IV criteria, and AD was assessed with the PO-SCORAD.The study evaluated the incidence of IC and AD, infant growth, and risk factors for IC and AD. Results: A total of 113 infants were in the BM group, 111 in the FF group, and 114 in the FF_2'-FL group. Maternal baseline characteristics, including delivery age ( Conclusion: This study suggests that supplementation with 2'-fucosyllactose may help reduce the risk of IC and AD. These findings have important implications for pediatric healthcare and support the development of preventive strategies for IC and AD beyond breastfeeding.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.